Aegerion Pharmaceuticals Inc. agreed to pay $40.1 million to resolve SEC and DOJ allegations that it made false claims about a cholesterol drug, federal authorities said Sept. 22.
The Cambridge, Mass.-based company, now a subsidiary of Novelion Therapeutics Inc., will plead guilty to misdemeanor charges and pay $36 million in its settlement with the Department of Justice over its marketing of Juxtapid, which treats high cholesterol in patients with a rare genetic disease, according to the agency.
Aegerion employees deceived doctors by telling them Juxtapid was appropriate for all patients with high cholesterol, DOJ said (United States v. Aegerion Pharmaceuticals Inc., D. Mass., No. 1:17-cr-10288, 9/22/17
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.